In two phase 1 crossover trials, propellant HFA-152a matched HFA-134a on mucociliary clearance in 22 healthy adults (ratio 1.00) and was non-inferior for FEV1 change at 15 min in 19 mild asthma patients (−0.37% vs −0.60%); adverse events were mild.
RCTn = 41
Singh et al. Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials